Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention.
about
Clinical development methodology for infusion-related reactions with monoclonal antibodiesTargeted nanotechnology for cancer imaging.Pre-clinical immunotoxicity studies of nanotechnology-formulated drugs: Challenges, considerations and strategyX-ray-computed tomography contrast agentsInteractions of nanomaterials and biological systems: Implications to personalized nanomedicineIncreased Duration of Heating Boosts Local Drug Deposition during Radiofrequency Ablation in Combination with Thermally Sensitive Liposomes (ThermoDox) in a Porcine ModelLipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.Renal retention of lipid microbubbles: a potential mechanism for flank discomfort during ultrasound contrast administration.Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targetingPegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patientsPhase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors.Mediation of a non-proteolytic activation of complement component C3 by phospholipid vesicles.Nanoparticles for imaging, sensing, and therapeutic intervention.FedExosomes: Engineering Therapeutic Biological Nanoparticles that Truly Deliver.Physicochemical signatures of nanoparticle-dependent complement activation.Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology.Preparation, physical characterization and pharmacokinetic study of paclitaxel nanocrystals.Accelerated blood clearance phenomenon upon cross-administration of PEGylated nanocarriers in beagle dogs.Properties and prospects of adjuvants in influenza vaccination - messy precipitates or blessed opportunities?Computed Tomography Imaging of Solid Tumors Using a Liposomal-Iodine Contrast Agent in Companion Dogs with Naturally Occurring Cancer.Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose studyTUNABLE COMPLEMENT ACTIVATION BY PARTICLES WITH VARIABLE SIZE AND Fc DENSITYGlutamine-Loaded Liposomes: Preliminary Investigation, Characterization, and Evaluation of Neutrophil Viability.Sustained delivery of proangiogenic microRNA-132 by nanoparticle transfection improves endothelial cell transplantation.Application of a hemolysis assay for analysis of complement activation by perfluorocarbon nanoparticles.Liposome technology for cardiovascular disease treatment and diagnosis.Particulate systems for targeting of macrophages: basic and therapeutic concepts.Translational immunologic safety evaluation: a perspective.Liposomes, a promising strategy for clinical application of platinum derivatives.Investigational drugs for coagulation disorders.Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines.Nanomedicine as an innovative therapeutic strategy for pediatric lung diseases.Merging the best of both worlds: hybrid lipid-enveloped matrix nanocomposites in drug delivery.Formation, clearance, deposition, pathogenicity, and identification of biopharmaceutical-related immune complexes: review and case studies.Complexity in the therapeutic delivery of RNAi medicines: an analytical challenge.Nanomedicine for the treatment of Alzheimer's disease.Strategy for selecting nanotechnology carriers to overcome immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics.Hypersensitivity to intravenous iron: classification, terminology, mechanisms and managementDextran-coated superparamagnetic nanoparticles as potential cancer drug carriers in vivo.Polyaspartamide-doxorubicin conjugate as potential prodrug for anticancer therapy.
P2860
Q26798184-61983075-D92D-459A-9EE8-2308C46F5CD1Q27010317-E409927F-8365-481B-A34D-1D0F749B8EAFQ28081577-167E80F4-9695-4059-9DF1-A8D591572819Q28280706-F6B2255D-5368-4484-94FA-302745A28BEFQ28391849-0D981802-4F97-493B-8E8F-18A43348E6DAQ28550019-E35683C3-091C-4120-BDEC-FB94C686797CQ30366990-DED830F3-2398-4E99-A9AD-A60A2D8025CBQ30424128-45DE18E9-08B1-4D8C-9F3B-49BBCE913489Q30456053-FC525710-1795-4DB4-899C-1629E1061F74Q33424387-13169511-E072-4448-9115-BD09D5284E73Q33437383-8E2DDA50-756D-469D-B963-8807A6F1AE21Q33925578-6AECE273-697E-443C-86D6-830F0DCA2E3BQ34010233-320DE147-8DB8-4A7C-93F2-D019A37A09A7Q34037648-D64594D7-1F91-4CF3-AEC9-FFA30F50F71EQ34218533-F4AF4604-DF63-4B2B-9C8B-AD748CC60D1FQ34447986-93263E55-E996-4B9A-81B7-94F6A059B2CBQ35231632-A138F6EF-D6BA-4118-AB32-627CD505E415Q35624235-3D21A992-59B4-4269-B416-6C5B50DF588BQ35664854-D9ADA0CD-1BC9-4AD4-84BC-664131CC81B1Q35975280-3B6C35C1-74E3-4837-9729-0516D4B44E38Q36025267-B020E58B-F84C-4B90-9801-E66F5544C625Q37137646-EC177F99-7FCA-4AB3-9E3E-FB60866BB8EFQ37175010-A9560C70-34FC-4C66-AAFF-9AC1EFC92D31Q37503636-9998F85B-2100-4EB1-91DF-7052AFBF3D7DQ37666126-258A6096-D769-4CE6-BD4B-184280E3EE06Q37974931-19B8C5FB-3E56-434A-BE18-11573742F16BQ38020769-B90252C0-3743-4B79-8E82-50A671F670ACQ38042463-FADB9E99-BD31-4D5E-991E-5E898BE1A124Q38087423-48496A0C-DE99-4480-9B33-E6129B9FF339Q38106245-3955942E-DDE4-4500-8B73-50814D5466DDQ38112504-BF1510DA-BC9C-456F-80AE-9DB449F182EBQ38133484-BDFBA34E-0E6F-4780-8775-30C582A014BCQ38150118-275E62BF-3627-40E6-93D7-BBE11D5CE5A2Q38202541-0902594F-2250-4AF2-A24A-5468E22DD4C8Q38221915-5F6F41F4-0507-4F82-917A-523ECCFA5FEDQ38451932-2BC5976B-674A-4F27-858C-3E09D233DBE8Q38494470-585652D5-7BD6-458E-93E9-EACED1D82613Q38564991-2295D885-BC40-406A-915D-2CA796C1DAB7Q38865350-C674AA81-9CD5-44A9-A415-FFF494E65BE0Q38943134-428DFAA9-0247-4A32-9538-53D6E555C9A6
P2860
Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Activation of complement by th ...... ts: prediction and prevention.
@en
Activation of complement by th ...... ts: prediction and prevention.
@nl
type
label
Activation of complement by th ...... ts: prediction and prevention.
@en
Activation of complement by th ...... ts: prediction and prevention.
@nl
prefLabel
Activation of complement by th ...... ts: prediction and prevention.
@en
Activation of complement by th ...... ts: prediction and prevention.
@nl
P2093
P1476
Activation of complement by th ...... ts: prediction and prevention.
@en
P2093
Alberto Gabizon
Janos Szebeni
Yechezkel Barenholz
P304
P356
10.1016/J.ADDR.2011.06.017
P407
P577
2011-07-14T00:00:00Z